BDSX (Biodesix) Debt-to-Equity : 2.22 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biodesix Debt-to-Equity?

Biodesix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.65 Mil. Biodesix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $61.30 Mil. Biodesix's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $27.86 Mil. Biodesix's debt to equity for the quarter that ended in Sep. 2024 was 2.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Biodesix's Debt-to-Equity or its related term are showing as below:

BDSX' s Debt-to-Equity Range Over the Past 10 Years
Min: -35.1 Med: 0.79 Max: 13.25
Current: 2.22

During the past 6 years, the highest Debt-to-Equity Ratio of Biodesix was 13.25. The lowest was -35.10. And the median was 0.79.

BDSX's Debt-to-Equity is ranked worse than
96.86% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.27 vs BDSX: 2.22

Biodesix Debt-to-Equity Historical Data

The historical data trend for Biodesix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodesix Debt-to-Equity Chart

Biodesix Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.16

0.67

0.51

1.55

13.25

Biodesix Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															-35.10	13.25	-11.12	1.70	2.22

Competitive Comparison of Biodesix's Debt-to-Equity

For the Diagnostics & Research subindustry, Biodesix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biodesix's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Biodesix's Debt-to-Equity falls into.

Biodesix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Biodesix's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.303	+	60.388)	/	4.58
	=	13.25

Biodesix's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.653	+	61.303)	/	27.857
	=	2.22

Biodesix (NAS:BDSX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Biodesix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Biodesix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Biodesix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biodesix Inc (NAS:BDSX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

919 West Dillon Road, Louisville, CO, USA, 80301

Website

https://www.biodesix.com

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Executives

Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Kennedy Lawrence T. Jr	director, 10 percent owner	C/O WESTWOOD MANAGEMENT, 1700 MADISON ROAD, SUITE 200, CINCINNATI OH 45206
Scott Hutton	director, officer: President & CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Kieran O'kane	officer: Chief Commercial Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Gary Anthony Pestano	officer: Chief Development Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Robin Harper Cowie	officer: CFO, Sec'y & Treasurer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Chris Vazquez	officer: Chief Accounting Officer	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
John Patience	director, 10 percent owner, other: Chairman	28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Matthew Strobeck	director	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Jon Faiz Kayyem	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Ryan H Siurek	officer: Chief Accounting Officer	6200 SPRINT PARKWAY, OVERLAND PARK KS 66251
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Georgantas Robert William Iii	director, officer: SVP, Rsrch & Trans'l Science	2970 WILDERNESS PLACE, SUITE 100, BOULDER CO 80301
Jean M. Franchi	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139